Media.Player

Triclosan: a First-of-its-Kind Biphenyl Compound to Increase the

Technology Benefits

Increases the efficacy of anthracycline therapy in cancer treatments. Reduces the cost of treating cancer patients due to more effective drugs used. Results in healthier cancer patients after treatment due to the reduced amount of metabolites causing cardiotoxicity.

Detailed Technology Description

Boise State University has developed a composition that reduces the negative permanent side effects of the chemotherapy drug anthracycline. It is anticipated that Triclosan may be administered along with anthracyclines as a cotherapy; or even pretreatment to block carbonyl reductase before administration. Most intriguing is the potential of triclosan in combination with one or more anthracycline compounds. This makes it attractive to companies developing improved formulations of adriamycin, daunomycin,daunorubicin, doxorubicin, epirubicin, and idarubicin.

Supplementary Information

Inventor: Charlier, Jr., Henry A. | Ewing, Christopher K.
Priority Number: US7781412B2
IPC Current: A01N004304 | A01N002700 | A01N002904 | A01N002910 | A61K0031015 | A61K0031025 | A61K003103 | A61K003170
US Class: 514034 | 514754 | 514755 | 514765
Assignee Applicant: Boise State University,Boise
Title: Biphenyl inhibitors of carbonyl reductase
Usefulness: Biphenyl inhibitors of carbonyl reductase
Summary: A pharmaceutical composition for preventing or reducing cardiotoxicity associated with anthracycline cancer chemotherapy (claimed).
Novelty: Pharmaceutical composition for preventing or reducing cardiotoxicity comprises anthracycline compound and enzyme inhibitor having two aryl groups connected with bridging atom, e.g. carbon, oxygen, sulfur, nitrogen, or their derivatives

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

*Abstract

Anthracyclines are the most commonly used chemotherapy agents for cancer, including leukemia, soft tissue sarcomas, and breast and lung cancer. However, in the body, an enzyme called carbonyl reductase causes anthracycline to be converted into metabolites ΓÇô which not only lowers the amount of cancer cells killed by a given dose, but also contributes to cardiotoxicity and drug resistance. We present the first biphenyl compound shown to significantly inhibit carbonyl reductase: Triclosan. Triclosan is an uncompetitive inhibitor against carbonyl-containing substrates (like anthracyclines). This results in lower doses of the anthracycline drugs that will be effective for cancer cell-killing.

*Principal Investigator

Name: Henry Charlier, Associate Professor

Department: Chemistry

Name: Christopher Ewing

Department:

Country/Region

USA